Compare studies Compare two to four sourced results, with the study details that make the numbers meaningful.
Research question Weight loss HbA1c Cardiovascular outcomes Lipid measurements Body composition Endpoint Body weight Effect measure Hazard ratio Published rate / risk ratio Estimate basis Change from baseline Difference vs placebo Difference vs active comparator
Add studies Find a study to compare 68 available results
ABBV-295 GUC17-01 multiple ascending dose study · Trial endpoint Weekly cohort 5a; dose not separately disclosed (study tested 2–14 mg) Add to comparison + Aleniglipron ACCESS · Trial endpoint 120 mg once daily Add to comparison + ASC30 ASC30-202 · Trial endpoint 60 mg once daily Add to comparison + Beinaglutide China phase 3 weight-management trial · Trial endpoint 0.2 mg three times daily Add to comparison + Berobenatide VESPER-3 · Trial endpoint 4.8 mg every 4 weeks after 0.4, 0.8 and 1.2 mg weekly, each for 4 weeks Add to comparison + Berobenatide VESPER-1 randomized double-blind Part A · Trial endpoint 1.2 mg once weekly Add to comparison + BGM0504 BGM0504-III-WL · Trial endpoint 15 mg once weekly Add to comparison + Bofanglutide Bofanglutide US phase 2 obesity trial · Trial endpoint 48 mg every two weeks Add to comparison + Cagrilintide REDEFINE 1 monotherapy comparator · Trial endpoint 2.4 mg once weekly Add to comparison + CagriSema REDEFINE 1 · Trial endpoint Cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly target Add to comparison + Conveglipron HDM1002 phase 2 obesity trial · Trial endpoint 400 mg once daily Add to comparison + CT-996 CT-996 multipart phase 1 · Trial endpoint Once daily; target dose not specified in source Add to comparison + Ecnoglutide SLIMMER · Trial endpoint 2.4 mg once weekly Add to comparison + Efsubaglutide alfa ENLIGHT phase 2b · Trial endpoint 20 mg once weekly Add to comparison + Elecoglipron VISTA · Trial endpoint 75 mg once daily; weekly dose escalation Add to comparison + Eloralintide 48-week phase 2 · Trial endpoint 9 mg once weekly Add to comparison + Enicepatide CT388-103 · Trial endpoint Up to 24 mg once weekly Add to comparison + HRS-4729 HRS-4729 phase 1 MAD · Trial endpoint 12 mg once weekly Add to comparison + HRS-7535 HARBOR-1 / HRS-7535-303 · Trial endpoint 180 mg once daily Add to comparison + Liraglutide SCALE Obesity and Prediabetes · Trial endpoint 3 mg once daily Add to comparison + MariTide MariTide phase 2 obesity cohort · Trial endpoint 420 mg every 4 weeks after 12-week dose escalation Add to comparison + Mazdutide GLORY-1 · Trial endpoint 6 mg once weekly Add to comparison + Mazdutide GLORY-2 non-T2D subgroup · Trial endpoint 9 mg once weekly Add to comparison + Oral ecnoglutide XW004 phase 1 cohort4 · Trial endpoint 30 mg daily Add to comparison + Oral ribupatide HRS9531 oral phase 2 · Trial endpoint 50 mg once daily Add to comparison + Oral semaglutide 25 mg OASIS 4 · Trial endpoint 25 mg once daily Add to comparison + Orforglipron ATTAIN-1 · Trial endpoint 36 mg once-daily trial capsule (bioequivalent approved tablet: 17.2 mg) Add to comparison + Pemvidutide MOMENTUM · Trial endpoint 2.4 mg once weekly Add to comparison + Petrelintide ZUPREME-1 · Trial endpoint Maximally effective once-weekly dose; dose level not specified in release Add to comparison + Poterepatide HDM1005 phase 2 obesity trial · Trial endpoint 4 mg once weekly Add to comparison + RAY1225 REBUILDING-1 · Trial endpoint 18 mg every two weeks Add to comparison + Retatrutide TRIUMPH-1 · Trial endpoint 12 mg once weekly Add to comparison + Ribupatide GEMINI-1 / HRS9531-301 · Trial endpoint 6 mg once weekly Add to comparison + Semaglutide 2.4 mg STEP 1 · Trial endpoint 2.4 mg once weekly Add to comparison + Semaglutide 7.2 mg STEP UP · Trial endpoint 7.2 mg once weekly Add to comparison + Survodutide SYNCHRONIZE-1 · Trial endpoint Up to 6.0 mg once weekly Add to comparison + TG103 TG103 phase 1b MAD · Trial endpoint 30 mg once weekly Add to comparison + Tirzepatide SURMOUNT-1 · Trial endpoint 15 mg once weekly Add to comparison + UBT251 UBT251 China phase 2 obesity trial · Trial endpoint 6 mg once weekly Add to comparison + VK2735 (oral) VENTURE-Oral · Trial endpoint 120 mg once daily after 6-week escalation Add to comparison + VK2735 (subcutaneous) VENTURE · Trial endpoint 15 mg once weekly Add to comparison + Zenagamtide (oral) First-in-human phase 1, Part C/D · Trial endpoint 2 × 50 mg tablets once daily (100 mg total), escalated Add to comparison + Zenagamtide (subcutaneous) Phase 1b/2a, Part B dose escalation · Trial endpoint Escalation up to 60 mg once weekly Add to comparison + CagriSema REDEFINE 9 · Trial endpoint Cagrilintide 1.0 mg + semaglutide 1.0 mg weekly target; flexible dosing Add to comparison + CagriSema REDEFINE 9 · Trial endpoint Cagrilintide 1.7 mg + semaglutide 1.7 mg weekly target; flexible dosing Add to comparison + Semaglutide 2.4 mg STEP 1 · Curve final visit 2.4 mg once weekly Add to comparison + Tirzepatide 15 mg SURMOUNT-1 · Curve final visit 15 mg once weekly Add to comparison + Retatrutide 12 mg TRIUMPH-1 · Curve final visit 12 mg once weekly Add to comparison + Ribupatide HRS9531-203 high-dose phase 2 · Curve final visit 8 mg weekly; 24-week escalation then 12-week maintenance Add to comparison + Aleniglipron ACCESS double-blind period · Curve final visit 90 mg orally once daily, escalated every 4 weeks Add to comparison + CagriSema REDEFINE 1 · Curve final visit Cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly target Add to comparison + Cagrilintide REDEFINE 1 monotherapy comparator · Curve final visit 2.4 mg once weekly Add to comparison + Liraglutide SCALE Obesity and Prediabetes · Curve final visit 3 mg once daily Add to comparison + Zenagamtide (subcutaneous) Phase 1b/2a, Part B dose escalation · Curve final visit Escalation up to 60 mg once weekly Add to comparison + Oral semaglutide 25 mg OASIS 4 · Curve final visit 25 mg once daily Add to comparison + VK2735 (subcutaneous) VENTURE · Curve final visit 15 mg once weekly Add to comparison + Survodutide SYNCHRONIZE-1 · Curve final visit Up to 6.0 mg once weekly Add to comparison + Enicepatide CT388-103 · Curve final visit Up to 24 mg once weekly Add to comparison + Petrelintide ZUPREME-1 · Curve final visit Trial Dose 3, once weekly; milligram regimen not disclosed in this presentation Add to comparison + Berobenatide VESPER-3 · Curve final visit 4.8 mg every 4 weeks after 0.4, 0.8 and 1.2 mg weekly, each for 4 weeks Add to comparison + ASC30 ASC30-202 · Curve final visit 60 mg orally once daily after weekly titration through 1, 2, 5, 10, 20 and 40 mg Add to comparison + RAY1225 REBUILDING-1 · Curve final visit 18 mg every two weeks Add to comparison + Mazdutide GLORY-1 · Curve final visit 6 mg subcutaneously once weekly after 4 weeks each at 2 mg and 4 mg Add to comparison + Ecnoglutide SLIMMER · Curve final visit 2.4 mg subcutaneously once weekly after 4-week titration steps of 0.3, 0.6, 1.2 and 1.8 mg Add to comparison + Tirzepatide SURMOUNT-5 · Randomized active comparison Maximum tolerated 10 or 15 mg weekly Add to comparison + Semaglutide SURMOUNT-5 · Randomized active comparison Maximum tolerated 1.7 or 2.4 mg weekly Add to comparison + CagriSema REDEFINE 4 · Randomized active comparison 2.4 mg cagrilintide + 2.4 mg semaglutide weekly Add to comparison + Tirzepatide REDEFINE 4 · Randomized active comparison 15 mg weekly Add to comparison +
0 of 4 results selected · choose at least two
Choose studies to compare Select two to four results for the same endpoint. Their efficacy, safety and study context will appear side by side.